Sensitization of dural afferents underlies migraine-related behavior following meningeal application of interleukin-6 (IL-6) by Yan, Jin et al.
RESEARCH Open Access
Sensitization of dural afferents underlies
migraine-related behavior following meningeal
application of interleukin-6 (IL-6)
Jin Yan
1, Ohannes K Melemedjian
1, Theodore J Price
1,2,3 and Gregory Dussor
1,2*
Abstract
Background: Migraine headache is one of the most common neurological disorders, but the pathophysiology
contributing to migraine is poorly understood. Intracranial interleukin-6 (IL-6) levels have been shown to be
elevated during migraine attacks, suggesting that this cytokine may facilitate pain signaling from the meninges
and contribute to the development of headache.
Methods: Cutaneous allodynia was measured in rats following stimulation of the dura with IL-6 alone or in
combination with the MEK inhibitor, U0126. The number of action potentials and latency to the first action
potential peak in response to a ramp current stimulus as well as current threshold were measured in retrogradely-
labeled dural afferents using patch-clamp electrophysiology. These recordings were performed in the presence of
IL-6 alone or in combination with U0126. Association between ERK1 and Nav1.7 following IL-6 treatment was also
measured by co-immunoprecipitation.
Results: Here we report that in awake animals, direct application of IL-6 to the dura produced dose-dependent
facial and hindpaw allodynia. The MEK inhibitor U0126 blocked IL-6-induced allodynia indicating that IL-6 produced
this behavioral effect through the MAP kinase pathway. In trigeminal neurons retrogradely labeled from the dura,
IL-6 application decreased the current threshold for action potential firing. In response to a ramp current stimulus,
cells treated with IL-6 showed an increase in the numbers of action potentials and a decrease in latency to the first
spike, an effect consistent with phosphorylation of the sodium channel Nav1.7. Pretreatment with U0126 reversed
hyperexcitability following IL-6 treatment. Moreover, co-immunoprecipitation experiments demonstrated an
increased association between ERK1 and Nav1.7 following IL-6 treatment.
Conclusions: Our results indicate that IL-6 enhances the excitability of dural afferents likely via ERK-mediated
modulation of Nav1.7 and these responses contribute to migraine-related pain behavior in vivo. These data provide
a cellular mechanism by which IL-6 in the meninges causes sensitization of dural afferents therefore contributing
to the pathogenesis of migraine headache.
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Background
Migraine is characterized as episodes of unilateral throb-
bing headache accompanied by a variety of symptoms,
including aura, nausea, vomiting, photophobia and pho-
nophobia [1]. Although the mechanisms contributing to
migraine pathophysiology are not fully known, one
hypothesis proposes that migraine is an inflammatory
disease [2]. This idea is supported by the efficacy of
non-steroidal anti-inflammatory drugs (NSAIDs) in
migraine therapy as well as increased intracranial levels
of inflammatory mediators during migraine attacks [2,3].
Interleukin-6 (IL-6), whichi so n es u c hm e d i a t o rf o u n d
to be elevated during migraine attacks [3,4], is a cyto-
kine with an established role in modulating various
inflammatory pain conditions, including skin incision,
carrageenan injection, burn-injury pain and pancreatitis-
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inflammatory conditions and increases in IL-6 parallel
pain intensity over time [10-12]. IL-6’s pain promoting
actions are thought to be mediated by a direct action on
nociceptors because sensory neuron specific knockout of
the IL-6 co-receptor reduces nociceptive sensitization
[13]. Moreover, neutralizing IL-6 using a monoclonal
antibody is effective in treating human rheumatoid
arthritis [14]. Thus, accumulating evidence points to IL-
6 as a contributing factor to many pain conditions pos-
sibly including migraine.
Activation and sensitization of meningeal nociceptors
leads to afferent signaling that is thought to contribute to
the headache that occurs during migraine. However, the
contribution of IL-6 to this process and the mechanisms
by which this may occur have not yet been explored. Fol-
lowing acute IL-6 application, trigeminal ganglion neu-
rons display phosphorylation of ERK [15] indicating that
these neurons respond to IL-6 through activation of the
Mitogen-Activated Protein Kinase (MAPK) signaling
pathway. Activation of the ERK1/2 MAPK pathway has
been implicated in induction and maintenance of various
pain conditions via transcriptional, translational or post-
translational regulation [15-17]. Recent work has identi-
fied the voltage-gated sodium channel Nav1.7 as a novel
downstream post-translational target for MAPK. Nav1.7
is a threshold sodium channel expressed on small and
medium DRG neurons [18] and inhibition of ERK1/2
decreased neuronal excitability by inhibiting Nav1.7
phosphorylation and altering its gating properties [19].
Taken together, these studies led us to propose that
increased levels of IL-6 in the meninges produces
migraine-related pain behavior and this hypothesis was
addressed using a preclinical model of headache. Further,
we examined whether dural afferent excitability was
increased following IL-6 exposure and whether this




Adult male Sprague Dawley rats (175-200 g) were main-
tained in a climate-controlled room on a 12 h light/dark
cycle with food and water ad libitum. All procedures
were performed in accordance with the policies and
recommendations of the International Association for
the Study of Pain, the National Institutes of Health
guidelines for the handling and use of laboratory ani-
mals, and were approved by the Institutional Animal
Care and Use Committee of the University of Arizona.
Surgical preparation
1. Tracer injection
Dural afferents were identified as previously
described [20,21]. Seven days prior to sacrifice, ani-
mals were anesthetized with a combination of keta-
mine and xylazine (80 mg/kg and 12 mg/kg; Sigma-
Aldrich). Two holes were made in the skull under a
dissecting microscope to carefully expose but not
damage the dura and fluorogold (5 μl/hole; 4% in
SIF, synthetic interstitial fluid, pH 7.4, 320 mOsm)
was applied onto the dura. A small piece of gelfoam
was retained in the hole to increase the absorption
of the dye and prevent spread of the tracer outside
of the hole. Holes were covered with bone wax to
prevent tracer spread. The incision was closed with
sutures. Immediately postoperatively, animals
received a single subcutaneous injection of gentami-
cin (8 mg/kg) to minimize infection. Undamaged
dura at the injection sites was evaluated at the time
the animals were sacrificed and only animals with
intact dura and no signs of damage were used for
further experiments.
2. Dural cannulation
Dura cannulae were implanted as previously
described [20,21]. Animals were anesthetized with a
combination of ketamine and xylazine (80 mg/kg
and 12 mg/kg; Sigma-Aldrich). A 2 cm incision was
made to expose the skull. A 1 mm hole was made in
the skull (above the transverse sinus; 2 mm left of
the sagittal suture and 2 mm anterior to the lamb-
doid suture) with a hand drill (DH-0 Pin Vise; Plas-
tics One, Roanoke, VA) to carefully expose the dura.
A guide cannula (22 GA, #C313G; Plastics One),
designed to extend 0.5 mm from the pedestal to
avoid irritation of the dural tissue, was inserted into
the hole and sealed into place with glue. Two addi-
tional 1 mm holes were made in the parietal bones
to receive stainless-steel screws (Small Parts), and
dental acrylic was used to fix the cannula to the
screws. A dummy cannula (#C313DC; Plastics One)
was inserted to ensure patency of the guide cannula.
Immediately postoperatively, animals received a sin-
gle subcutaneous injection of gentamicin (8 mg/kg)
to minimize infection. Rats were housed separately
and allowed 6 to 8 days of recovery.
Cell culture
1. Whole-cell patch clamp
Seven days following fluorogold application, trigem-
inal ganglia were removed, enzymatically treated,
and mechanically dissociated as previously described
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Pharmaceuticals) and sacrificed by decapitation. The
trigeminal ganglion (TG) were removed and placed
in ice-cold Hanks balanced-salt solution (divalent
free). Ganglia were cut into small pieces and incu-
bated for 25 mins in 20 U/ml Papain (Worthington)
followed by 25 mins in 3 mg/ml Collagenase TypeII
(Worthington). Ganglia were then triturated through
fire-polished pasteur pipettes and plated on poly-D-
lysine (Becton Dickinson) and laminin (Sigma)-
coated plates. After several hours at room tempera-
ture to allow adhesion, cells were cultured in a
room-temperature, humidified chamber in Liebovitz
L-15 medium supplemented with 10% FBS, 10 mM
glucose, 10 mM HEPES and 50 U/ml penicillin/
streptomycin. Cells were used within 24 h post
plating.
2. Western Blotting
Rat trigeminal ganglia (TG) were excised aseptically
and placed in Hank’sB u f f e r e dS a l tS o l u t i o n( H B S S ,
Invitrogen) on ice. The ganglia were dissociated enzy-
matically with collagenase A (1 mg/ml, 25 min,
Roche) and collagenase D (1 mg/ml, Roche) with
papain (30 U/ml, Roche) for 20 min at 37°C. To elim-
inate debris, 70 μm (BD) cell strainers were used. The
dissociated cells were resuspended in DMEM/F12
(Invitrogen) containing 1X pen-strep (Invitrogen), 1X
GlutaMax, 3 μg/ml 5-FDU (5-Fluoro-2’-deoxyuridine)
(Sigma), 7 μg/ml uridine (Sigma) and 10% fetal
bovine serum (Hyclone). The cells were plated in 6-
well plates (BD Falcon) and incubated at 37°C in a
humidified 95% air/5%CO2 incubator. On day 5 the
cells were washed in DMEM/F12 media for 15 mins
followed by treatment.
Electrophysiology
Whole cell patch-clamp experiments were performed on
isolated rat TG using a MultiClamp 700B (Axon Instru-
ments) patch-clamp amplifier and pClamp 10 acquisi-
tion software (Axon Instruments). Recordings were
sampled at 2 kHz and filtered at 1 kHz (Digidata 1322A,
Axon Instruments). Pipettes (OD: 1.5 mm, ID: 0.86 mm,
Sutter Instrument) were pulled using a P-97 puller (Sut-
ter Instrument) and heat polished to 2.5-4 MΩ resis-
tance using a microforge (MF-83, Narishige). Series
resistance was typically < 7 MΩ and was compensated
60-80%. All recordings were performed at room tem-
perature. A Nikon TE2000-S Microscope equipped with
a mercury arc lamp (X-Cite
® 120) was used to identify
FG-labeled dural afferents. Data were analyzed using
Clampfit 10 (Molecular Devices) and Origin 8
(OriginLab). Cell sizes were not significantly different
among groups (Vehicle: 38.91 ± 2.214 pF vs IL-6: 39.62
± 1.712 pF vs IL-6 + U0126: 41.98 ± 2.526 pF, p > 0.05).
Pipette solution contained (in mM) 140 KCl, 11 EGTA,
2M g C l 2, 10 NaCl, 10 HEPES, 1 CaCl2 pH 7.3 (adjusted
with N-methyl glucamine), and was ~ 320 mosM. Exter-
nal solution contained (in mM) 135 NaCl, 2 CaCl2,1
MgCl2, 5 KCl, 10 Glucose, 10 HEPES, pH 7.4 (adjusted
with N-methyl glucamine), and was ~ 320 mosM.
Behavioral testing
Rats were acclimated to suspended Plexiglas chambers
(30 cm long × 15 cm wide × 20 cm high) with a wire
mesh bottom (1 cm2). Ten μl of vehicle or testing solu-
tion was injected through an injection cannula (28GA,
#C313I; Plastics One) cut to fit the guide cannula. With-
drawal thresholds to probing the face and hind-paws
were determined at 1-h intervals after administration. A
behavioral response to calibrated von Frey filaments
applied to the midline of the forehead, at the level of
the eyes, was indicated by a sharp withdrawal of the
head. Paw withdrawal (PW) thresholds were determined
by applying von Frey filaments to the plantar aspect of
the hind-paws, and a response was indicated by a with-
drawal of the paw. The withdrawal thresholds were
determined by the Dixon up-down method [22]. Maxi-
mum filament strengths were 8 and 15 g for the face
and hind-paws, respectively.
Western blotting
Protein was extracted from cells in lysis buffer (50 mM
Tris HCl, 1% Triton X-100, 150 mM NaCl, and 1 mM
EDTA at pH 7.4) containing protease and phosphatase
inhibitor mixtures (Sigma) with an ultrasonicator on ice,
and cleared of cellular debris and nuclei by centrifuga-
tion at 14,000 RCF for 15 min at 4°C. Fifteen micro-
grams of protein per well were loaded and separated by
standard 7.5% or 10% SDS-PAGE. Proteins were trans-
ferred to Immobilon-P membranes. Blots were incu-
bated with primary antibody overnight at 4°C and
detected the following day with appropriate secondary
antibodies. Signal was detected by ECL on chemilumi-
nescent films. Densitometric analyses were performed
with Image J software (NIH).
Co-immunoprecipitation
After protein extraction, 70 μg protein was incubated
with Nav1.7 antibody (NeuroMab) overnight at 4°C fol-
lowed by 3 h incubation with 20 μl protein G-Sepharose
beads. After washing 3 times with lysis buffer, the pel-
leted beads were resuspended in 1X Laemmli Sample
Buffer containing 5% v/v b-mercaptoethanol and total
ERK (tERK) bound to the precipitated beads was ana-
lyzed by western blotting.
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All data are presented as means ± SEM unless otherwise
noted. Statistical evaluation was performed by linear
regression analysis, unpaired t-test, one-way analysis of
variance (ANOVA) followed by post hoc Newman-Keuls
test, or two-way ANOVA. For behavioral experiments,
data were converted to area over the time-effect curve
to allow for multiple comparisons.
Chemicals
Fluorogold was purchased from Fluorochrome, LLC.
and dissolved in synthetic interstitial fluid (SIF) (pH
7.4, 310 mOsm) to 4%. U0126 was from Tocris Bios-
ciences. Rat recombinant IL-6 was from R&D Systems.
Stock U0126 (10 mM) was prepared in Dimethyl sulf-
oxide (DMSO) and added to the culture media and the
recording chamber to produce a final concentration of
10 μM in 0.1% DMSO for patch experiment. For the
behavioral experiments, stock U0126 solutions (100
mM in DMSO) were prepared and diluted in SIF to
the final concentration of 1 mM. Vehicle control was
SIF with 1% DMSO. Stock rIL-6 (10 μg/ml) was pre-
pared in sterile 0.1% BSA in PBS and diluted to final
concentrations of 50 ng/ml (patch) and 100 ng/ml
(behavior), respectively.
Results
Cutaneous allodynia following IL-6 administration to the
dura
A preclinical in vivo migraine model was used to eval-
uate the effect of meningeal IL-6 application on
mechanical withdrawal thresholds both to the face and
hindpaws [23]. Mechanical allodynia following dural
stimulation is used as a surrogate for migraine as the
majority of migraine patients experience cutaneous
allodynia during the headache phase and allodynia is
more common in migraine compared to other types of
headaches [24,25]. Application of 1 ng IL-6 in SIF
solution to the dura produced significant (p < 0.0001)
time-dependent reductions in withdrawal thresholds to
tactile stimuli applied to the face or the hind-paws
compared with SIF application alone (Figure 1A). Max-
imal effects occurred 2 h after IL-6 application, and
facial and hind-paw allodynia was present for at least
24 h (Figure 1A). IL-6 dose-dependently reduced the
withdrawal thresholds compared with vehicle control
as 1 ng IL-6 produced greater allodynia than that
observed at 0.1 ng (Figure 1B). Co-application of the
MEK inhibitor, U0126 (10 nmol) with 1 ng IL-6 pre-
vented facial and hind-paw cutaneous allodynia (Figure
1C), indicating that IL-6 produces allodynia following
dural application via activation of the MAP kinase
(ERK) signaling pathway.
Activation of the ERK pathway mediates IL-6-induced
hyperexcitability of dural afferents
Nav1.7 is known to generate currents in response to
slow ramp depolarization due to its slow inactivation
kinetics, hence a ramp stimulus protocol was used to
preferentially elicit activity of Nav1.7 [26]. Although this
protocol elicits activation of Nav1.7 it should be noted
that other sodium channels such as Nav1.8 may also be
recruited as Nav1.7 and Nav1.8 are thought to work
together in generating repetitive firing in sensory neu-
rons [27,28]. Thus, this protocol likely produces firing
via activation of multiple sodium channels but an
increase in firing is nonetheless indicative of Nav1.7
sensitization.
Retrogradely-labeled cells in vitro were selected for
patch clamp experiments. Slow ramp currents from 0.1
to 0.7 nA with Δ = 0.2 nA were injected over 1 s (Figure
2A) to mimic slow depolarization. If cells fired in
response to this protocol no further testing is done. If
they did not fire with this protocol, a second protocol
was run where the final ramp amplitude is 2 nA in 1 s.
If cells fire in response to this protocol they were
included in the data analysis as they technically
responded to a ramp current injection but they are
given 0 spikes for 0.1, 0.3, 0.5, and 0.7 nA since they did
not fire in response to any of the slower ramps. If they
did not fire in response to the 2 nA ramp they were
excluded from analysis as they were determined to be
cells that likely would not fire in response to a ramp.
Dural afferents acutely treated with 50 ng/ml IL-6 for
15 min showed a significant increase in the number of
spikes and a decrease in the latency to the first AP spike
(Figure 2A and 2B), consistent with increased Nav1.7
activity. Pretreatment with 10 μM U0126 for 10 min sig-
nificantly reversed the IL-6-induced increase in excit-
ability (Figure 2A and 2B) indicating that, similar to IL-
6 induced allodynia, these changes are due to activation
of ERK signaling.
Current clamp configuration was used to determine
the current threshold, i.e. the minimum current required
to initiate an action potential in the same group of dural
afferents. Action potentials were elicited by injecting
rectangular current steps (25 ms, Δ =1 0p A ) .T h ec u r -
rent threshold was significantly decreased for dural
afferents acutely pretreated with IL-6 for 15 mins (217.4
± 17.98 nA, n = 31) compared with dural afferents trea-
ted with vehicle (319.3 ± 25.14 nA, n = 30, **p <0 . 0 1v s
vehicle) (Figure 3A and 3B). Although there was no
depolarization of the resting membrane potential follow-
ing IL-6 treatment, pretreatment with the MEK inhibitor
U0126 significantly hyperpolarized resting membrane
potentials (-67.24 ± 1.474 mV) compared with vehicle
(-63.45 ± 0.7208, p < 0.05) or IL-6 treated neurons
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tent with previous studies of Nav1.7 where U0126 treat-
ment hyperpolarized resting membrane potentials [19].
Pretreatment with the MEK inhibitor U0126 for 10
mins reversed the IL-6-induced changes in current
threshold (374.6 ± 52.45 nA, n = 13,
##p <0 . 0 1v sI L - 6
alone), again indicating that IL-6 acts through the MAP
kinase pathway.
IL-6 treatment promotes direct association between ERK
and Nav1.7
To further explore whether IL-6-induced hyperexcitabil-
ity of dural afferents was mediated through modulation
of Nav1.7, we used a co-immunoprecipitation assay to
determine direct associations between ERK and Nav1.7.
In cells treated with IL-6 for 15 min, a significantly
increased (*p < 0.05) amount of tERK was co-immuno-
precipited with Nav1.7 compared to vehicle treatment
(Figure 4A and 4B) although there was no change in the
total level of Nav1.7 (data not shown). Pretreatment
with the MEK inhibitor U0126 for 10 mins significantly
reversed (*p < 0.05) the IL-6-induced increase in asso-
ciation between Nav1.7 and ERK. No signal was seen
with cell lysates without primary antibody incubation
(Figure 4A, Neg). In contrast to the observation that
both tERK1 and tERK2 were detected in whole cell
lysates (Figure 4A, Input), only tERK1 was detected in
co-IP analysis (Figure 4A), consistent with a previous
Figure 1 Application of IL-6 to the dura elicited cutaneous allodynia via activation of the MEK/ERK pathway.( A) Withdrawal thresholds
to tactile stimuli applied to the face and the hind-paws were measured in rats before and immediately after dural application of 1 ng IL-6 (n =
16) or SIF (n = 17). For both facial and hind-paw responses, two-factor analysis of variance indicated that response thresholds of IL-6-treated rats
were significantly (p < 0.0001) less than those of SIF-treated rats. (B) Rats received dural administration of SIF (white bar, n = 17), 0.1 ng IL-6
(gray bar, n = 22) or 1 ng IL-6 (black bar, n = 16). Withdrawal thresholds to tactile stimuli were measured for 5 h and data were converted to
area over the time-effect curve. IL-6 dose-dependently decreased the withdrawal threshold both in the face and in the hind-paw. Significant (*p
< 0.05, **p < 0.01) differences among means for each group were determined by analysis of variance followed by Newman-Keuls post hoc test.
(C) Application of 1 ng IL-6 was given with vehicle (white bars, 1% DMSO, n = 12) or with U0126 (black bars, 1 nmol, n = 12). Withdrawal
thresholds to tactile stimuli were measured for 5 h and data were converted to area over the time-effect curve and normalized as a percentage
of the IL-6-treated group. Coapplication of U0126 significantly abolished behavioral signs of tactile allodynia of the face and hind-paw (*p < 0.05,
**p < 0.01).
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were elicited by 1 s ramp current injection ranging from 0.1 to 0.7 nA in 0.2 nA increments from resting membrane potential. Dural afferents
treated with IL-6 showed increased numbers of action potentials and shorter time-to-first action potential (AP) peak compared with vehicle-
treated dural afferents. IL-6-induced hyperexcitability was blocked by pretreatment with 10 μM U0126. (B) Difference in the mean numbers of
action potentials among groups was analyzed by comparing the slopes and intercepts generated from linear regression. Comparison among
several groups for time-to-first spike was performed by two-factor analysis of variance. Dural afferents treated with 50 ng/ml IL-6 (red square, n =
16) showed a significant (p < 0.05) increase in number of action potentials and a significant decrease in time-to-first peak compared with
vehicle-treated dural afferents (black circle, n = 12). Pretreatment with 10 μM U0126 (blue triangle, n = 13) for 10 mins significantly reversed IL-6-
induced hyperexcitability.
Figure 3 IL-6 treatment significantly increased the dural afferent excitability, which was blocked by pretreatment with U0216.( A)
Current threshold was measured in dural afferents treated with vehicle (white bar, n = 30), 50 ng/ml IL-6 (black bar, n = 32) or 50 ng/ml IL-6 +
10 μM U0126 (gray bar, n = 13). Significant (**p < 0.01) differences among means for each group were determined by analysis of variance
followed by Newman-Keuls post hoc test. Current threshold was significantly lowered after IL-6 treatment (**p < 0.01). Pretreatment with U0126
for 10 mins significantly reversed the hyperexcitability induced by IL-6 (
##p < 0.01). (B) Action potentials were elicited by 25 ms step current
injection from resting membrane potential. Horizontal line and arrow indicate 0 and -70 mV membrane potential, respectively. Current threshold
for action potentials in the representative dural afferents treated with vehicle, 50 ng/ml IL-6 or 50 ng/ml IL-6 + 10 μM U0126.
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t h eL 1l o o po fN a v 1 . 7[ 1 9 ] .T h e s ed a t ap r o v i d ef u r t h e r
evidence that IL-6-activated signaling pathways can reg-
ulate neuronal excitability through direct modulation of
Nav1.7.
Discussion
Understanding the endogenous processes that promote
the activation and sensitization of meningeal nociceptors
is important in explaining the mechanisms underlying
migraine headache. The present findings provide direct
evidence that IL-6 is important for sensitization of dural
afferents by increasing neural excitability through modu-
lation of Nav1.7. We also demonstrate that meningeal
IL-6 application can produce migraine-like behavior
through activation of the ERK pathway, supporting a
role for IL-6 in migraine pathophysiology.
These studies demonstrate that direct meningeal
application of exogenous IL-6 caused migraine-like
behaviors in rats. However, the source of endogenous
IL-6 during a migraine attack is not clear. Several lines
of evidence have indicated that neurogenic inflammation
underlies migraine headache pathogenesis with the
involvement of at least 2 types of immune cells, dural
mast cells and meningeal macrophages [29,30]. The
meninges are densely populated with mast cells, which
reside in close proximity to afferent endings mostly
within the dura compared to other meningeal layers
[31-33]. A variety of well-known migraine precipitants,
including stress (via the release of corticotrophin releas-
ing hormone CRH or factor CRF) and CGRP trigger
mast cell degranulation and the subsequent release of
their inflammatory mediators [29]. Relevant to the stu-
dies described here are reports that human mast cells
can release IL-6 following stimulation [34,35]. In addi-
tion to mast cells, IL-6 released from dural macrophages
may also contribute to stress-induced neurogenic
inflammation [30]. Regardless of the source, IL-6 has
the ability to sensitize nociceptors through actions on
TRPV1 and ERK-mediated signaling to translation
machinery [15,36]. The experiments described here
demonstrated that IL-6 application was able to sensitize
identified dural afferents, and suggested additional
mechanisms of IL-6 induced sensitization through phos-
phorylation of sodium channels.
Human genetic studies have demonstrated an impor-
tant role for the sodium channel Nav1.7 in pain [37].
Gain-of-function mutations of Nav1.7 are directly
linked with several extreme pain conditions in humans
such as erythromelalgia and paroxysmal extreme pain
disorder, whereas loss-of-function mutation of Nav1.7
is associated with congenital insensitivity to pain [37].
Although the gain-of-function mutations do not lead
to headache and the location specific nature of the
spontaneous pain in these disorders is poorly under-
stood, these conditions highlight the importance of
this channel in nociceptive signaling and suggest that
sensitization of Nav1.7 may contribute to enhanced
pain signaling from many areas including the head.
Due to its distinctive slow development of closed-state
inactivation, Nav1.7 is able to generate current in
response to sub-threshold depolarization, thus playing
an important role in amplifying excitatory inputs and
modulating neuronal excitability [26]. Additionally,
inhibition of Nav1.7 is known to decrease neuronal
excitability [38,39]. Preclinical work has also indicated
an important role for Nav1.7 in mediating inflamma-
tory pain as supported by the evidence that formalin-
induced mechanical allodynia and thermal hyperalgesia
are abrogated in Nav1.7 knockout mice [40]. Moreover,
mRNA and protein levels of Nav1.7 increase following
carrageenan injection, which parallel the increase in
TTX-S currents [41]. Hence, preclinical and clinical
Figure 4 IL-6 enhanced direct association between ERK1 and
Nav1.7. Western blot and quantification for tERK following 15 mins
treatment of TG cultures with vehicle, IL-6 (50 ng/ml) or IL-6 (50 ng/
ml) + U0126 (10 μM) (A) Interaction between ERK and Nav1.7 was
examined by immunoprecipitation (IP) with antibody against Nav1.7
followed by immunoblotting (IB) for tERK. Omission of primary
antibody was used as negative control and whole cell lysates were
loaded as positive control. (B) ERK1 was quantified and values were
expressed as percentage of vehicle. Significant (*p < 0.05)
differences among means for each group were determined by
analysis of variance followed by Newman-Keuls post hoc test.
Yan et al. Molecular Pain 2012, 8:6
http://www.molecularpain.com/content/8/1/6
Page 7 of 9studies have created a compelling rationale for target-
ing Nav1.7 in inflammatory pain. The present work
indicates that IL-6 application increases the number of
spikes and decreases the latency to the first AP in
response to ramp stimuli protocols, which are consis-
tent with hyperexcitability induced by Nav1.7 phos-
phorylation [19]. This IL-6-induced hyperexcitability is
mediated through ERK signaling, which is similar to
prior work showing that inhibition of ERK1/2
decreases excitability in DRG neurons [19]. Addition-
ally, and consistent with the previous study showing
that pERK1, but not pERK2 phosphorylated the L1
loop of Nav1.7 [19], increased association between
ERK1 and Nav1.7 was detected following IL-6 treat-
ment, indicating that IL-6-activated signaling pathways
are capable of modulating Nav1.7 directly. While we
cannot rule out the possibility that modulation of
other channels contributes to electrophysiological
effects following IL-6 treatment, the findings reported
here support the hypothesis that IL-6 produces sodium
channel-dependent hyperexcitability and migraine-
related behavior through activation of the ERK
pathway.
Conclusions
This study provides direct evidence that IL-6 can sensi-
tize dural afferents in a manner consistent with sodium
channel phosphorylation and that it produces prolonged
migraine-related pain behavior through activation of the
ERK pathway. Although there is currently no direct link
between Nav1.7 and migraine, these findings suggest
that an IL-6/Nav1.7 signaling axis can be an important
mediator of headache pain and that drugs targeting IL-6
signaling may have efficacy in the treatment of migraine
headache.
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